drugset / Trial / NCT04953663

Clinical Plan of Ischemic Stroke

NCT04953663 ↗

Phase 1/2 Unknown 60 enrolled Peking University Third Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Stroke is the main cause of adult health damage. 20% of stroke survivors need institutional care after 3 months, and up to 30% of them have severe or permanent disability. Stem cells are a kind of pluripotent cells with the ability of self replication. The self-renewal and differentiation characteristics of mesenchymal stem cells, as well as cytokine secretion effect and immune characteristics, provide the possibility for mesenchymal stem cells to treat ischemic stroke. After the infusion of mesenchymal stem cells, the secretion of soluble media including growth factors and cytokines may be the main mechanism of mesenchymal stem cells.

Timeline

Start
2021-01-01
Primary completion
2022-01-01
Completion
2023-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject it-hMSC Cell therapy 500000 cells/kg Intravenous
Subject it-hMSC Cell therapy 1e+06 cells/kg Intravenous
Subject it-hMSC Cell therapy 2e+06 cells/kg Intravenous

Indications